HUP0402088A3 - Substituted piperazine and piperidine compounds pharmaceutical compositions containing them and their use for the preparation of a medicament for inhibiting fatty acid oxidation - Google Patents

Substituted piperazine and piperidine compounds pharmaceutical compositions containing them and their use for the preparation of a medicament for inhibiting fatty acid oxidation

Info

Publication number
HUP0402088A3
HUP0402088A3 HU0402088A HUP0402088A HUP0402088A3 HU P0402088 A3 HUP0402088 A3 HU P0402088A3 HU 0402088 A HU0402088 A HU 0402088A HU P0402088 A HUP0402088 A HU P0402088A HU P0402088 A3 HUP0402088 A3 HU P0402088A3
Authority
HU
Hungary
Prior art keywords
medicament
preparation
fatty acid
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0402088A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Cv Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics filed Critical Cv Therapeutics
Publication of HUP0402088A2 publication Critical patent/HUP0402088A2/hu
Publication of HUP0402088A3 publication Critical patent/HUP0402088A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57Aryl or substituted aryl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lubricants (AREA)
  • Paper (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HU0402088A 2001-07-19 2002-07-18 Substituted piperazine and piperidine compounds pharmaceutical compositions containing them and their use for the preparation of a medicament for inhibiting fatty acid oxidation HUP0402088A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30662101P 2001-07-19 2001-07-19
PCT/US2002/022897 WO2003008411A1 (en) 2001-07-19 2002-07-18 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors

Publications (2)

Publication Number Publication Date
HUP0402088A2 HUP0402088A2 (hu) 2005-02-28
HUP0402088A3 true HUP0402088A3 (en) 2010-03-29

Family

ID=23186103

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402088A HUP0402088A3 (en) 2001-07-19 2002-07-18 Substituted piperazine and piperidine compounds pharmaceutical compositions containing them and their use for the preparation of a medicament for inhibiting fatty acid oxidation

Country Status (21)

Country Link
US (1) US6930111B2 (enExample)
EP (1) EP1406898B1 (enExample)
JP (1) JP2004537554A (enExample)
KR (1) KR100919141B1 (enExample)
CN (1) CN1533388A (enExample)
AT (1) ATE292633T1 (enExample)
AU (1) AU2008202958A1 (enExample)
CA (1) CA2454059A1 (enExample)
DE (1) DE60203623T2 (enExample)
DK (1) DK1406898T3 (enExample)
ES (1) ES2236557T3 (enExample)
HU (1) HUP0402088A3 (enExample)
IL (1) IL159897A0 (enExample)
MX (1) MXPA04000565A (enExample)
NO (1) NO327635B1 (enExample)
NZ (1) NZ530705A (enExample)
PL (1) PL368529A1 (enExample)
PT (1) PT1406898E (enExample)
RU (1) RU2300533C2 (enExample)
WO (1) WO2003008411A1 (enExample)
ZA (1) ZA200400404B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001909B2 (en) * 2001-07-19 2006-02-21 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
KR20050033070A (ko) 2002-08-09 2005-04-08 아스트라제네카 에이비이 메타보트로픽 글루타메이트 수용체-5의 조절제로서[1,2,4]옥사디아졸
NZ538339A (en) * 2002-08-09 2007-01-26 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
CA2495179A1 (en) 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
EP1806346B1 (en) * 2002-12-05 2009-07-22 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
CA2508608A1 (en) * 2002-12-05 2004-06-24 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
WO2004063180A1 (en) 2003-01-03 2004-07-29 Cv Therapeutics, Inc. Substituted heterocyclic compounds
JP2006515891A (ja) * 2003-01-17 2006-06-08 シーブイ・セラピューティクス・インコーポレイテッド 循環器疾患の処置に有効な置換ヘテロ環化合物
EP1644345A1 (en) * 2003-06-23 2006-04-12 Cv Therapeutics, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
CA2550257A1 (en) * 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
JP2007517550A (ja) 2004-01-02 2007-07-05 アドヴァンスド カーディオヴァスキュラー システムズ, インコーポレイテッド 高比重リポ蛋白をコーティングした医療デバイス
WO2006029179A2 (en) * 2004-09-08 2006-03-16 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
WO2008023248A2 (en) 2006-08-24 2008-02-28 Wockhardt Research Centre Novel macrolides and ketolides having antimicrobial activity
US8088920B2 (en) * 2008-03-31 2012-01-03 Hoffmann-La Roche Inc. 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
SMT202000257T1 (it) 2008-10-10 2020-07-08 Vm Discovery Inc Composizioni e metodi per il trattamento dei disturbi da uso di alcol, dolore e altre malattie
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ, インコーポレイテッド Cns障害の治療のためのラノラジン
JPWO2011115150A1 (ja) * 2010-03-18 2013-07-04 興和株式会社 ベンゾチアジン化合物の製造方法
CN111285819A (zh) * 2018-12-07 2020-06-16 江苏恩华药业股份有限公司 一种苯并噁唑类化合物及其应用
WO2023023995A1 (zh) * 2021-08-25 2023-03-02 苏州大学 一种防治心肌缺血后心功能衰竭的药物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1133989A (en) 1964-12-08 1968-11-20 Chugai Pharmaceutical Co Ltd Theophylline derivatives, their salts and process for preparing the same
DE2834114A1 (de) * 1978-08-01 1980-02-14 Schering Ag Polyalkoxyphenylpyrrolidone iii, verfahren zu ihrer herstellung und ihre verwendung
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
JPS6137765A (ja) * 1984-07-19 1986-02-22 サンド・アクチエンゲゼルシヤフト 3‐アミノプロポキシアリール誘導体
US4723014A (en) * 1986-11-19 1988-02-02 Warner-Lambert Company Process for the preparation of 2-substituted-1,4-dihydropyridines
DE3723648A1 (de) * 1987-07-17 1989-01-26 Sandoz Ag Indol-derivate, ihre herstellung und sie enthaltende arzneimittel
JPH0699399B2 (ja) * 1988-10-06 1994-12-07 三井東圧化学株式会社 新規複素環化合物およびそれを有効成分として含有する製癌剤効果増強剤
JPH02268162A (ja) * 1989-04-10 1990-11-01 Fujisawa Pharmaceut Co Ltd ジフェニルピリジン誘導体
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
JP2001503769A (ja) * 1996-11-14 2001-03-21 アメリカン・ホーム・プロダクツ・コーポレイション 抗アテローム性動脈硬化症薬としての置換テトラヒドロ―1,3,5―トリアジン―2[1h]―チオン
HUP0202679A3 (en) * 1999-09-13 2003-04-28 Wyeth Corp Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols, process for their preparation and pharmaceutical compositions containing them
SE9904765D0 (sv) 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
US6677343B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
BR0108592A (pt) * 2000-02-22 2004-06-29 Cv Therapeutics Inc Compostos de piperazina substituìda
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
WO2001062711A2 (en) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
SE0003795D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives

Also Published As

Publication number Publication date
HUP0402088A2 (hu) 2005-02-28
PT1406898E (pt) 2005-08-31
CN1533388A (zh) 2004-09-29
DE60203623T2 (de) 2006-01-19
US20030181352A1 (en) 2003-09-25
JP2004537554A (ja) 2004-12-16
US6930111B2 (en) 2005-08-16
ATE292633T1 (de) 2005-04-15
PL368529A1 (en) 2005-04-04
WO2003008411A1 (en) 2003-01-30
MXPA04000565A (es) 2005-06-17
AU2002322527B2 (en) 2008-04-17
NO20040234L (no) 2004-03-18
KR100919141B1 (ko) 2009-09-25
KR20040029374A (ko) 2004-04-06
EP1406898A1 (en) 2004-04-14
NZ530705A (en) 2005-08-26
HK1064374A1 (en) 2005-01-28
NO327635B1 (no) 2009-09-07
ZA200400404B (en) 2004-10-14
ES2236557T3 (es) 2005-07-16
AU2002322527A2 (en) 2003-03-03
CA2454059A1 (en) 2003-01-30
EP1406898B1 (en) 2005-04-06
AU2008202958A1 (en) 2008-07-31
RU2004104951A (ru) 2005-06-27
DK1406898T3 (da) 2005-05-30
IL159897A0 (en) 2004-06-20
DE60203623D1 (de) 2005-05-12
RU2300533C2 (ru) 2007-06-10

Similar Documents

Publication Publication Date Title
HUP0402088A3 (en) Substituted piperazine and piperidine compounds pharmaceutical compositions containing them and their use for the preparation of a medicament for inhibiting fatty acid oxidation
HUP0302656A3 (en) Fumaric acid amides, their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing the compounds
HUP0303552A3 (en) Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors and pharmaceutical compositions containing them
IL162213A0 (en) Pharmaceutical compositions containing active vitamin d compounds
HUP0204496A3 (en) Novel piperidine compounds and pharmaceutical compositions containing the same and process for preparation the same
HUP0303810A3 (en) Carboxylic acid derivative and salt thereof and pharmaceutical compositions containing them
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
HUP0203431A3 (en) Novel heterocyclic compounds and salts thereof and pharmaceutical compositions containing and use of the same
HUP0303325A3 (en) Pharmaceutical salts and pharmaceutical compositions containing them
PL356358A1 (en) Solid dosage form of someticone for oral administration
EE200200021A (et) Asendamatuid rasvhappeid ja homotsüsteiini taset alandavaid aineid sisaldavad farmatseutilised ühendid ja toidulisandid
HUP0302358A3 (en) Piperazinedione compounds and use of them for producing pharmaceutical compositions
HUP0301391A3 (en) Piperazine and piperidine derivatives pharmaceutical compositions containing them and their use
HUP0202867A3 (en) Piperazine derivatives useful as ccr5 antagonists and pharmaceutical compositions containing them
HUP0401333A3 (en) Spiropyrazole compounds and pharmaceutical compositions containing them
HUP0500017A3 (en) Alkyl ether derivatives or salts thereof and pharmaceutical compositions containing them
HUP0204458A3 (en) Derivatives of quinoline as alpha-2 antagonists and pharmaceutical compositions containing them
HUP0203311A3 (en) New pharmaceutical compositions of prolonged effect
IL161430A0 (en) Pharmaceutical compositions containing ecteinascidin 743
HUP0401747A3 (en) Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
IL162325A0 (en) Hiv integrase inhibitor compounds and pharmaceutical compositions containing the same
HUP0203787A3 (en) Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent, pharmaceutical compositions containing them and their use
HUP0400386A3 (en) Tablet comprising cetirizine and pseudoephedrine and its use for preparation of pharmaceutical compositions
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient
IL161348A (en) Substituted 4- phenyl-4-[1h - imidazol-2-yl] piperidine derivatives and their use for the preparation of pharmaceutical compositions

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished